ADAMTS12 is a stromal modulator in chronic liver disease
The FASEB Journal · 2023
DOI: 10.1096/fj.202200692rrrr ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Bassil Dekky und 8 weiteren Autor:innen. Beteiligte Einrichtung: University of Rennes, INSERM, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, Rennes, France. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fonds De La Recherche Scientifique - FNRS, Ligue Contre le Cancer.
Abstract (Originalsprache)
Adamalysins, a family of metalloproteinases containing a disintegrin and metalloproteinases (ADAMs) and ADAM with thrombospondin motifs (ADAMTSs), belong to the matrisome and play important roles in various biological and pathological processes, such as development, immunity and cancer. Using a liver cancer dataset from the International Cancer Genome Consortium, we developed an extensive in silico screening that identified a cluster of adamalysins co‐expressed in livers from patients with hepatocellular carcinoma (HCC). Within this cluster, ADAMTS12 expression was highly associated with recurrence risk and poorly differentiated HCC signatures. We showed that ADAMTS12 was expressed in the stromal cells of the tumor and adjacent fibrotic tissues of HCC patients, and more specifically in activated stellate cells. Using a mouse model of carbon tetrachloride‐induced liver injury, we showed that A damts12 was strongly and transiently expressed after a 24 h acute treatment, and that fibrosis was exacerbated in Adamts12 ‐null mice submitted to carbon tetrachloride‐induced chronic liver injury. Using the HSC‐derived LX‐2 cell line, we showed that silencing of ADAMTS12 resulted in profound changes of the gene expression program. In particular, genes previously reported to be induced upon HSC activation, such as PAI‐1, were mostly down‐regulated following ADAMTS12 knock‐down. The phenotype of these cells was changed to a less differentiated state, showing an altered actin network and decreased nuclear spreading. These phenotypic changes, together with the down‐regulation of PAI‐1, were offset by TGF‐β treatment. The present study thus identifies ADAMTS12 as a modulator of HSC differentiation, and a new player in chronic liver disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Rennes, INSERM, EHESP, IRSET (Institut de Recherche en Santé, Environnement et Travail)-UMR_S 1085, Rennes, France.
- Laboratory of Connective Tissues Biology, GIGA-R, University of Liege, Liege, Belgium.
ORCID-Profile: Bassil Dekky, Fida Azar, Alain Colige, Vincent Legagneux, Nathalie Théret
Förderung
- Fonds De La Recherche Scientifique - FNRS
- Ligue Contre le Cancer
Zitieren
APA
Dekky, B., Azar, F., Bonnier, D., Monseur, C., Kalebić, C., Arpigny, E., Colige, A., Legagneux, V., & Théret, N. (2023). ADAMTS12 is a stromal modulator in chronic liver disease. The FASEB Journal. https://doi.org/10.1096/fj.202200692rrrr
Vancouver
Dekky B, Azar F, Bonnier D, Monseur C, Kalebić C, Arpigny E, et al. ADAMTS12 is a stromal modulator in chronic liver disease. The FASEB Journal. 2023. doi:10.1096/fj.202200692rrrr
BibTeX
@article{Dekky2023,
author = {Dekky, Bassil and Azar, Fida and Bonnier, Dominique and Monseur, Christine and Kalebić, Chiara and Arpigny, Esther and Colige, Alain and Legagneux, Vincent and Théret, Nathalie},
title = {ADAMTS12 is a stromal modulator in chronic liver disease},
journal = {The FASEB Journal},
year = {2023},
doi = {10.1096/fj.202200692rrrr}
}
EUVIMED